Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.
To inquire about participation in a clinical trial, please contact us at (804) 893-8717.
Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.
Search Clinical Trials
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with …
A Randomized, Phase III Clinical Trial of Low‐Dose Tamoxifen for Selected Patients with Molecular Low-risk Early‐Stage Breast Cancer
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with …
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, …
AYA ACCESS Study: An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant …
A Randomized Phase 2 Non-inferiority Trial of (Z)-Endoxifen + Goserelin Versus Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women …
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with …
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN ADULT …
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients …
